The B4GALT1 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population harboring a disrupted B4GALT1 gene. This loss-of-function model is generated in the PaTu 8988t pancreatic ductal adenocarcinoma host cells, providing a heterogeneous knockout background that retains biological complexity. The polyclonal format is suited for population-level studies of glycobiology and cancer signaling without clonal bias.
The PaTu 8988t cell line is derived from a primary human pancreatic ductal adenocarcinoma, a devastating malignancy with poor prognosis. It serves as a robust model for pancreatic cancer research, faithfully recapitulating tumor cell characteristics such as aberrant growth, invasive capacity, and altered glycosylation. Its wide use in drug screening and metastasis studies makes it an ideal host for interrogating glycogene function.
B4GALT1 encodes a Golgi-resident ??-1,4-galactosyltransferase that adds galactose to N-acetylglucosamine on glycoproteins and glycolipids, generating Gal??1-4GlcNAc structures. Its expression is regulated by the SP1 transcription factor and EGF signaling, and its activity depends on UDP-galactose as sugar donor and interaction with chaperones like COSMC. In the presence of ??-lactalbumin, it forms lactose synthase in the mammary gland. Downstream, it modifies glycoproteins such as LAMP1, LAMP2, and integrins, affecting their stability and cell-surface function. B4GALT1-catalyzed galactosylation is critical for N-glycan maturation, O-glycan processing, and glycosphingolipid biosynthesis.
In pancreatic cancer, altered N-glycosylation promotes tumor progression. Disruption of B4GALT1 in PaTu 8988t cells ablates terminal galactosylation, leading to truncated glycans and potential loss of integrin-mediated adhesion and signaling. This phenotypic shift can reduce migratory and invasive behavior, revealing glycosylation-dependent mechanisms that drive metastasis. These cells thus enable the dissection of glycan-specific contributions to pancreatic cancer aggressiveness.
These knockout cells are instrumental for lectin blotting, flow cytometric glycan profiling, and mass spectrometry-based glycomics to map glycosylation changes. Migration and invasion assays can directly assess metastatic potential. Immunoprecipitation of galactosylated targets like LAMP1 allows glycoprotein-focused studies. This model is also valuable for therapeutic target validation in glycosylation-related pathways. For further information, contact Ascent Research.
